A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Name: A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
Published: 2017
License: Public Domain

AbbVie · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

arthritis

rheumatoid arthritis (ra), musculoskeletal disease, arthritis, joint disease, anti-inflammatory agents, antirheumatic agents, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Related documents